vs
Side-by-side financial comparison of Chaince Digital Holdings Inc. (CD) and Mind Medicine (MindMed) Inc. (DFTX). Click either name above to swap in a different company.
Mind Medicine (MindMed) Inc. is the larger business by last-quarter revenue ($906.0K vs $466.6K, roughly 1.9× Chaince Digital Holdings Inc.). Chaince Digital Holdings Inc. runs the higher net margin — -640.5% vs -2634.0%, a 1993.5% gap on every dollar of revenue.
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
CD vs DFTX — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $466.6K | $906.0K |
| Net Profit | $-3.0M | $-23.9M |
| Gross Margin | — | — |
| Operating Margin | -665.1% | -2450.8% |
| Net Margin | -640.5% | -2634.0% |
| Revenue YoY | — | -16.1% |
| Net Profit YoY | — | -386.7% |
| EPS (diluted) | $-0.05 | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $466.6K | — | ||
| Q4 23 | — | $906.0K | ||
| Q3 23 | — | $1.2M | ||
| Q2 23 | — | $1.3M | ||
| Q1 23 | — | $1.3M | ||
| Q4 22 | — | $1.1M | ||
| Q3 22 | — | $360.0K | ||
| Q1 22 | — | $-27.0K |
| Q2 25 | $-3.0M | — | ||
| Q4 23 | — | $-23.9M | ||
| Q3 23 | — | $-17.9M | ||
| Q2 23 | — | $-29.1M | ||
| Q1 23 | — | $-24.8M | ||
| Q4 22 | — | $-4.9M | ||
| Q3 22 | — | $-16.5M | ||
| Q1 22 | — | $-18.5M |
| Q2 25 | -665.1% | — | ||
| Q4 23 | — | -2450.8% | ||
| Q3 23 | — | -1858.6% | ||
| Q2 23 | — | -2226.1% | ||
| Q1 23 | — | -1624.8% | ||
| Q4 22 | — | -1287.0% | ||
| Q3 22 | — | -4717.5% | ||
| Q1 22 | — | 68537.0% |
| Q2 25 | -640.5% | — | ||
| Q4 23 | — | -2634.0% | ||
| Q3 23 | — | -1541.1% | ||
| Q2 23 | — | -2222.0% | ||
| Q1 23 | — | -1932.6% | ||
| Q4 22 | — | -454.0% | ||
| Q3 22 | — | -4579.2% | ||
| Q1 22 | — | 68337.0% |
| Q2 25 | $-0.05 | — | ||
| Q4 23 | — | $-0.58 | ||
| Q3 23 | — | $-0.45 | ||
| Q2 23 | — | $-0.76 | ||
| Q1 23 | — | $-0.65 | ||
| Q4 22 | — | $-0.02 | ||
| Q3 22 | — | $-0.56 | ||
| Q1 22 | — | $-0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.2M | $99.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $29.4M | $78.1M |
| Total Assets | $36.6M | $124.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $27.2M | — | ||
| Q4 23 | — | $99.7M | ||
| Q3 23 | — | $117.7M | ||
| Q2 23 | — | $116.9M | ||
| Q1 23 | — | $129.4M | ||
| Q4 22 | — | $142.1M | ||
| Q3 22 | — | $154.5M | ||
| Q1 22 | — | $120.5M |
| Q2 25 | $29.4M | — | ||
| Q4 23 | — | $78.1M | ||
| Q3 23 | — | $96.0M | ||
| Q2 23 | — | $106.0M | ||
| Q1 23 | — | $130.3M | ||
| Q4 22 | — | $150.9M | ||
| Q3 22 | — | $153.6M | ||
| Q1 22 | — | $136.8M |
| Q2 25 | $36.6M | — | ||
| Q4 23 | — | $124.5M | ||
| Q3 23 | — | $141.6M | ||
| Q2 23 | — | $142.1M | ||
| Q1 23 | — | $155.5M | ||
| Q4 22 | — | $170.0M | ||
| Q3 22 | — | $180.9M | ||
| Q1 22 | — | $149.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $-20.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-1.3M | — | ||
| Q4 23 | — | $-20.6M | ||
| Q3 23 | — | $-16.6M | ||
| Q2 23 | — | $-13.8M | ||
| Q1 23 | — | $-13.3M | ||
| Q4 22 | — | $-12.8M | ||
| Q3 22 | — | $-9.3M | ||
| Q1 22 | — | $-12.9M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
